HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A case of successful treatment with telaprevir-based triple therapy for hepatitis C infection after treatment failure with vaniprevir-based triple therapy.

Abstract
Recently direct-acting antiviral agents, such as hepatitis C virus (HCV) non-structural 3/4A (NS3/4A) protease inhibitors (PI), have been introduced, and triple therapy regimens that include PI with conventional pegylated interferon α and ribavirin have significantly improved the sustained virological response (SVR) rate, up to 80% for both treatment-naïve and treatment-experienced patients with HCV genotype 1. We here report for the first time a case of the successful treatment of HCV genotype 1 infection with a first generation PI drug (telaprevir) based triple therapy after treatment failure with a second generation PI drug (vaniprevir) based triple therapy. A 67-year-old treatment-naïve Japanese man with HCV genotype 1b infection took part in a phase III clinical trial of vaniprevir-based triple therapy. His serum HCV RNA had become undetectable at week 2 and SVR was highly expected, but HCV RNA reappeared at week 4 after vaniprevir treatment. Polymerase chain reaction direct sequence of the HCV NS3/4A gene at week 8 after vaniprevir treatment showed the emergence of a vaniprevir-resistance mutation (D168V), the probable reason for the treatment failure. Six months later, retreatment with telaprevir-based triple therapy was started. Although the dosages of telaprevir and ribavirin had to be reduced due to severe anemia, the patient achieved an SVR. This case shows the value of repeating PI-based triple therapy with a different drug, a process that would reduce the chance of drug resistant mutation.
AuthorsKoji Takayama, Norihiro Furusyo, Eiichi Ogawa, Motohiro Shimizu, Satoshi Hiramine, Fujiko Mitsumoto, Kazuya Ura, Kazuhiro Toyoda, Masayuki Murata, Jun Hayashi
JournalJournal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy (J Infect Chemother) Vol. 20 Issue 9 Pg. 577-81 (Sep 2014) ISSN: 1437-7780 [Electronic] Netherlands
PMID25000830 (Publication Type: Case Reports, Journal Article)
CopyrightCopyright © 2014 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Chemical References
  • Antiviral Agents
  • Cyclopropanes
  • Indoles
  • Isoindoles
  • Lactams, Macrocyclic
  • Oligopeptides
  • Sulfonamides
  • telaprevir
  • Proline
  • vaniprevir
  • Leucine
Topics
  • Aged
  • Antiviral Agents (therapeutic use)
  • Cyclopropanes
  • Hepacivirus (isolation & purification)
  • Hepatitis C (drug therapy)
  • Humans
  • Indoles (therapeutic use)
  • Isoindoles
  • Lactams, Macrocyclic
  • Leucine (analogs & derivatives)
  • Male
  • Oligopeptides (therapeutic use)
  • Proline (analogs & derivatives)
  • Sulfonamides
  • Treatment Failure

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: